Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares in the company, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Amphastar Pharmaceuticals Stock Down 0.2 %
Shares of AMPH stock traded down $0.07 during trading hours on Wednesday, reaching $43.57. 328,155 shares of the company’s stock were exchanged, compared to its average volume of 399,011. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.09 billion, a PE ratio of 14.52, a PEG ratio of 0.87 and a beta of 0.78. The stock’s fifty day moving average price is $47.26 and its two-hundred day moving average price is $44.62.
Analysts Set New Price Targets
AMPH has been the topic of a number of analyst reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $60.33.
Institutional Trading of Amphastar Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares in the last quarter. Epoch Investment Partners Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 35.1% during the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after buying an additional 280,390 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Amphastar Pharmaceuticals by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock valued at $44,674,000 after acquiring an additional 14,015 shares during the period. American Century Companies Inc. raised its stake in Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after acquiring an additional 121,764 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after acquiring an additional 338,653 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
- Five stocks we like better than Amphastar Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- The Great CPU Race: AMD and Intel Battle for Dominance
- How to Read Stock Charts for Beginners
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.